Stat

STAT+: Pharmalittle: We’re reading about Trump team mov...

Trump administration probing extent to which pharmaceutical imports may threaten...

There could finally be a new gonorrhea treatment 

Plus more health news stories you need to read today.

STAT+: At Harvard, scientists worry over the consequenc...

Researchers at Harvard and its affiliates appreciate that the university resiste...

Opinion: No, I don’t want an AI scribe to write my pulm...

“I don’t think an algorithm can re-create the specifically human experiences” of...

Opinion: The NIH called my health equity research ‘anti...

The NIH canceled Logan Beyer’s health equity research, saying it was “antithetic...

STAT+: Universities begin search for indirect-cost fix ...

Academic groups announced an effort to develop a “simple and easily explained mo...

STAT+: At Harvard, worry over the consequences of resis...

Researchers at Harvard and its affiliates appreciate that the university resiste...

STAT+: Attorneys general want Congress to prohibit PBMs...

State AGs are concerned about conflicts of interest that allow PBMs to dominate ...

STAT+: Trump administration launches probe into pharmac...

The Trump administration disclosed that it had formally opened an investigation ...

STAT+: An interview with Christi Grimm, and ‘existentia...

This week in health care news: An interview with the fired HHS watchdog, inside ...

STAT+: Canada advances an antitrust probe into Express ...

Canadian officials have obtained a court order that requires Express Scripts to ...

Pfizer discontinues its experimental GLP-1 pill

Biotech news stories of the day, brought to you by The Readout.

STAT+: Pharmalittle: We’re reading about Pfizer halting...

Pfizer said it would stop development of danuglipron, its experimental oral GLP-...

STAT+: How a downturn in biotech may be felt in Kendall...

We may be witnessing a remaking of biotech — including the famed Kendall Square ...

Autism and the gut-brain connection

The health news stories you need to read this morning.

STAT+: Verve gene-editing therapy lowers cholesterol wi...

Verve Therapeutics said Monday that initial data show that its investigational g...

STAT+: Pfizer to discontinue its GLP-1 pill for obesity...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it ...

Verve gene-editing therapy lowers cholesterol without s...

Verve Therapeutics said Monday that initial data show that its investigational g...

Pfizer to discontinue its GLP-1 pill for obesity due to...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it ...

Closure of CDC hepatitis lab imperils U.S. outbreak res...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blo...

Opinion: STAT+: Biotech investors: Stop expecting CRISP...

The recent wave of layoffs and financial troubles at CRISPR-focused startups sho...

Why CDC cuts are being called ‘the greatest gift to tob...

The Office on Smoking and Health at the CDC is no more, putting state quitlines ...

Opinion: ‘Most-favored nation’ drug pricing has three s...

There are many good reasons why the U.S. should pay more for earlier access to n...

Tech modernization at community health centers in limbo...

A program to upgrade technology used by community health centers across the coun...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.